Sanofi's Big Bet on a Rare Nerve Disease Just Hit a Wall

The logic was elegant: if autoimmune attacks on nerve insulation are driven by this classical complement cascade, then blocking it early should protect the nerves. Sanofi's Phase 2 data looked encouraging enough to launch two big Phase 3 trials in 2024. MOBILIZE targeted refractory patients. A sister study called VITALIZE focused on patients already receiving immunoglobulin therapy.

MOBILIZE enrolled around 140 patients across multiple countries, randomized to riliprubart or placebo. Then came the interim analysis.

The Futility Verdict

On June 10, 2026, Sanofi announced what no drug developer wants to hear: the independent data monitoring committee concluded the trial was "unlikely to provide sufficient efficacy." In clinical trial speak, that's a futility call. The data strongly suggested that even if the trial ran to completion, it wouldn't prove riliprubart works in this population.

Critically, no safety red flags were found. The drug appears safe enough; it just doesn't appear to do enough.

This distinction matters. A safety failure can kill an entire drug. A futility failure raises a different question: was it the drug, or was it the target population? Refractory CIDP patients are, by definition, the toughest cases. Their disease has already shrugged off multiple treatments. Blocking one complement pathway may simply not be enough when the immune system has multiple ways to cause damage.

William Blair analyst Myles Minter called the result "disappointing for the complement inhibitor class in CIDP," while noting that trial design and diagnostic challenges in this population could have muddied the picture.

What Happens to the Rest of the Program?

Sanofi said it will evaluate whether VITALIZE, the other Phase 3 CIDP trial, should continue. That review is ongoing. The company also noted that stopping MOBILIZE won't create significant costs or change its 2026 financial guidance, which tells you something about how the market had already priced this program.

Indeed, Sanofi's stock barely flinched. Shares traded roughly flat after the announcement, suggesting Wall Street wasn't counting on riliprubart in CIDP as a major revenue driver anytime soon.

A Wider Setback for Complement Drugs in Nerve Disease

This isn't just a Sanofi story. The MOBILIZE failure sends a cautionary signal across the complement inhibitor landscape in neuromuscular disease.

Complement-targeting drugs have had real wins elsewhere. Alexion's ravulizumab and eculizumab (both C5 blockers) are approved in generalized myasthenia gravis and NMOSD. UCB's zilucoplan, a self-injectable C5 inhibitor, won FDA approval for myasthenia gravis in late 2023. Annexon's C1q-targeting antibody reported positive Phase 3 data in Guillain-Barré syndrome in 2024.

But CIDP, especially the refractory form, may be a different beast. The disease is heterogeneous (meaning it probably isn't one disease but several wearing the same name), and the role of complement varies from patient to patient. Blocking one pathway while leaving others intact might be like plugging one hole in a colander.

Dianthus Therapeutics is watching closely. Its drug claseprubart is running a Phase 3 trial called CAPTIVATE in CIDP, with interim results announced in March 2026. argenx, meanwhile, is pursuing CIDP from a different angle entirely with its FcRn inhibitor Vyvgart, and some analysts think Sanofi's stumble could strengthen argenx's competitive position by reducing the perceived threat from complement-based rivals.

Sanofi's Neurology Playbook After the Hit

This isn't Sanofi's first neurology setback. The company has been rebuilding its brain-focused pipeline after earlier disappointments, shifting toward a strategy that doesn't hinge on any single late-stage asset. Recent moves include acquiring Vigil Neuroscience and its oral TREM2 agonist VG-3927 for Alzheimer's disease, which had completed Phase 1 and was being readied for Phase 2, signaling a pivot toward neurodegeneration and earlier-stage science.

The company still has immunology as its bread and butter (dupilumab, anyone?), and broader neuroimmunology programs in MS and related disorders remain active. But the CIDP franchise just got a lot smaller.

The Bigger Picture

For the roughly 20 to 30% of CIDP patients who don't respond to existing treatments, the search for something better continues. The biology is complicated, the patient population is small, and clinical trials in rare diseases are notoriously hard to run.

Riliprubart's failure doesn't mean complement inhibition is wrong for nerve disease. It means the approach didn't work in the toughest patients, with this particular drug, in this particular trial. Science is full of elegant theories that crumble on contact with human biology.

The question now: can anyone crack the code for refractory CIDP, or will this remain one of neurology's stubborn unsolved puzzles? Dianthus, argenx, and others are still in the ring. The next 12 months will tell us a lot.

Hackers Hit the World's Biggest Pharma Company. Then They Got Greedy.

A hacking group claims it stole over a terabyte of Novo Nordisk's most sensitive data, including AI models, drug formulas, and clinical trial records, then demanded $25 million. The company refused to pay. Now the data is hitting the dark web.